Umbralisib has ‘distinct’ safety profile

Micrograph showing CLL
Phase 1 trial results suggest umbralisib, a PI3Kδ/CK1ε inhibitor, can be safe and active in patients with relapsed or refractory B-cell malignancies. Researchers said the safety profile of umbralisib “was distinct from that of other PI3Kδ inhibitors,” as it produced few immune-mediated adverse events (AEs). Umbralisib also produced an objective response rate of 37% in the entire study cohort, 80% in patients with chronic lymphocytic leukemia (CLL), 53% in patients with follicular lymphoma (FL), and 31% in patients with diffuse large B-cell lymphoma (DLBCL). [Read Article]

FDA approves new use for Zika test

Blood for transfusion
Photo from UAB Hospital
The US Food and Drug Administration (FDA) has approved an additional use for the cobas Zika test. The approval allows for the streamlined screening of multiple individual blood or plasma donations that have been pooled together. The cobas Zika test is a qualitative in vitro nucleic acid screening test for the direct detection of Zika virus RNA in plasma specimens from blood donors. [Read Article]

Study reveals gender imbalance in cancer research funding

Researchers in the lab
Photo by Rhoda Baer
A new study suggests male investigators in the UK receive more funding for cancer research than their female counterparts. Researchers analyzed funding for more than 4000 studies and found that male primary investigators (PIs) were consistently awarded more funding. The total investment value was 3.6 times greater for male PIs than for female PIs. The mean award value was 1.6 times greater, and the median award value was 1.3 times greater for males. [Read Article]